KT
Kevin Tang Portfolio
Invests via Tang Capital Management LLC | Managed by Kevin Tang
Invests via Tang Capital Management LLC
Managed by Kevin Tang
Automatically Tracked
Kevin Tang Profile
With a robust background in technology and finance, Kevin Tang has emerged as an influential figure in the venture capital landscape. His career encompasses significant roles at several leading tech startups, where he not only shaped product development but also guided strategic investments aimed at growth acceleration. Known for his expertise in scaling early-stage companies, he has been instrumental in navigating competitive markets to establish lasting brand presence. Kevin's insights into emerging technologies position him uniquely within investor circles, driving capital towards innovative solutions that address contemporary challenges.
With a robust background in technology and finance, Kevin Tang has emerged as an influential figure in the venture capital landscape. His career encompasses significant roles at several leading tech startups, where he not only shaped product development but also guided strategic investments aimed at growth acceleration. Known for his expertise in scaling early-stage companies, he has been instrumental in navigating competitive markets to establish lasting brand presence. Kevin's insights into emerging technologies position him uniquely within investor circles, driving capital towards innovative solutions that address contemporary challenges.
Investment Philosophy & Strategy
Opportunities in cutting-edge technologies shape Kevin Tang's investment outlook, emphasizing a strong commitment to fostering innovation. His experience with early-stage ventures equips him to identify disruptive trends and allocate resources effectively within dynamic markets. By integrating operational insights from his time at notable startups, he ensures strategic initiatives align closely with market needs, enhancing scalability potential. This focus on growth-oriented investments facilitates the development of solutions that not only thrive but also redefine industries. As an advocate for emerging tech, his strategy revolves around leveraging unique market positions to drive impactful change.
Opportunities in cutting-edge technologies shape Kevin Tang's investment outlook, emphasizing a strong commitment to fostering innovation. His experience with early-stage ventures equips him to identify disruptive trends and allocate resources effectively within dynamic markets. By integrating operational insights from his time at notable startups, he ensures strategic initiatives align closely with market needs, enhancing scalability potential. This focus on growth-oriented investments facilitates the development of solutions that not only thrive but also redefine industries. As an advocate for emerging tech, his strategy revolves around leveraging unique market positions to drive impactful change.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
184.3%
Gain +0.54%
Monthly
0.09%
Yearly
1.05%
Drawdown
90.08%
$2.51B
Equity
Holdings
$2.51B
Investment
$1.67B
$515.33M
Profit +$9.29M
Realized
-$325.33M
Unrealized
$840.66M
Dividends
$55.24M
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
0.54%
Profit
$9.29M
Win %
63%
This Week
Compared To Last Week
Gain
-3.11%
Profit
-$80.48M
Win %
63%
This Month
Compared to last month
Gain
-4.33%
Profit
-$113.55M
Win %
63%
This Year
Compared to last year
Gain
5.44%
Profit
$117.9M
Win %
64%
SVNT
SVNTQ
+94.47%
+$401,278.43 5640
56400PAA0
+90.1%
+$10.56M DEPO
DEPO
+31.27%
+$4.93M 
BGMSP Cyclacel Pharmaceuticals, Inc. - 6% Convertible Preferred Stock
+29.62%
+$11,918.48 0906
09061GAC5
+23.44%
+$1.69M 4588
45884XAE3
+14.37%
+$1.88M 
PLRX Pliant Therapeutics Inc.
+10%
+$543,052.93 
VKTX Viking Therapeutics Inc.
+7.46%
+$950,000 
STOK Stoke Therapeutics Inc.
+5.8%
+$675,000 
MNKD MannKind Corporation
+5.63%
+$1,118.19 
EOLS Evolus Inc.
+4.85%
+$169,057.35 
MRNA Moderna, Inc.
+4.51%
+$1.02M 
AGIO Agios Pharmaceuticals Inc.
+4.36%
+$135,000 
GLPG Galapagos NV American Depositary Receipt
+4.2%
+$4.58M 
LENZ LENZ Therapeutics, Inc.
+4.08%
+$63,155.96 
HRTX Heron Therapeutics Inc.
+4.01%
+$90,625.06 
BNTX BioNTech SE
+1.74%
+$723,800 
NUVB Nuvation Bio Inc.
+1.6%
+$236,216.77 
INSM Insmed Inc.
+1.45%
+$369,200 
KNSA Kiniksa Pharmaceuticals International, plc
+1.4%
+$2.49M 
AUPH Aurinia Pharmaceuticals Inc.
+0.72%
+$1.47M 
SPY SPDR S&P 500 ETF Trust
+0.28%
+$367,916.64 
UTHR United Therapeutics Corporation
+0.27%
+$147,998.1 
PGEN Precigen Inc.
+0.07%
+$32,087.5 
ABEO Abeona Therapeutics Inc.
0%
$0 
ALT Altimmune, Inc.
0%
$0 
ANAB AnaptysBio Inc.
0%
$0 
ANIP Ani Pharmaceuticals Inc.
0%
$0 
ARVN Arvinas Inc.
0%
$0 
AVIR Atea Pharmaceuticals Inc.
0%
$0 
BIIB Biogen Inc.
0%
$0 
CAPR Capricor Therapeutics Inc.
0%
$0 
CBIO Crescent Biopharma, Inc.
0%
$0 
CELC Celcuity Inc.
0%
$0 
CHRS Coherus Biosciences Inc.
0%
$0 
CMPS Compass Pathways plc Depositary Receipt
0%
$0 
CMPX Compass Therapeutics Inc.
0%
+$0.17 
CORT Corcept Therapeutics Incorporated
0%
$0 
DERM Journey Medical Corp
0%
$0 
DNTH Dianthus Therapeutics Inc.
0%
$0 
ERAS Erasca, Inc.
0%
$0 
FATE Fate Therapeutics Inc.
0%
$0 
IDYA Ideaya Biosciences Inc.
0%
$0 
IMCR Immunocore Holdings plc American Depositary Receipt
0%
$0 
JANX Janux Therapeutics Inc.
0%
$0 
KALV KalVista Pharmaceuticals Inc.
0%
$0 
LXRX Lexicon Pharmaceuticals, Inc.
0%
$0 
MIRM Mirum Pharmaceuticals Inc.
0%
$0 
NMRA Neumora Therapeutics, Inc.
0%
$0 
OPK Opko Health Inc.
0%
$0 
PMVP PMV Pharmaceuticals, Inc.
0%
$0 
PTCT PTC Therapeutics, Inc.
0%
$0 
RCKT Rocket Pharmaceuticals Inc.
0%
$0 
TARS Tarsus Pharmaceuticals Inc.
0%
$0 
URGN Urogen Pharma Ltd.
0%
$0 
VRDN Viridian Therapeutics Inc.
0%
$0 
WVE Wave Life Sciences Ltd.
0%
$0 
SYRE Spyre Therapeutics, Inc.
0%
$0 
ACHN Achillion Pharmaceuticals Inc
0%
$0 6402
640268AH1
0%
$0 VPHM
VPHM
0%
$0 OPTR
OPTR
0%
$0 RDEA
RDEA
0%
$0 AVNR
AVNR
0%
$0 NEOP
NEOP
0%
$0 CADX
CADX
0%
$0 SOMX
SOMX
0%
$0 7954
795435AB2
0%
$0 0082
00826TAG3
0%
$0 6932
69329YAA2
0%
$0 
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 1594 | Longs Won 727/1594 45% | Profit Factor 1.34 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $8.66M |
| Average Win $2.79M | Best Trade (Oct 16) $101.98M | Sharpe Ratio -29.87 |
| Average Loss -$1.74M | Worst Trade (Mar 30) -$200.88M | Z-Score -6.89 (100%) |
| Commissions $0 | Avg. Trade Length 1y 4m 2w 6d | Expectancy $323,291.99 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.05% | 0.81% | 10.27% |
| Consecutive Losing Trades | 1,439 | 1,295 | 1,151 | 1,007 | 863 | 719 | 576 | 432 | 288 | 144 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| 0082 00826TAG3 | 71.35M | $71.29M | $71.29M | - | - | - | 0.0 |
| 0906 09061GAC5 | 3M | $7.21M | $8.9M | - | $1.69M | 23.44% | +23.444% |
| 2482 24823QAB3 | 4M | $4.31M | $3.78M | - | -$530,000 | -12.3% | -12.297% |
| 2482 24823QAC1 | 9.81M | $6.79M | $5.99M | - | -$798,452.22 | -11.76% | -11.756% |
| 4588 45884XAE3 | 17M | $13.1M | $14.98M | - | $1.88M | 14.37% | +14.369% |
| 5640 56400PAA0 | 22.32M | $11.72M | $22.28M | - | $10.56M | 90.1% | +90.101% |
| 6402 640268AH1 | 69.91M | $70.14M | $70.14M | - | - | - | 0.0 |
| 6932 69329YAA2 | 37.47M | $43.14M | $43.14M | - | - | - | 0.0 |
| 7954 795435AB2 | 3M | $15.51M | $15.51M | - | - | - | 0.0 |
| 8051 80517QAA8 | 10M | $2.67M | $2.4M | - | -$275,047 | -10.28% | -10.282% |
| ABEO Abeona Therapeutics Inc. | 400,000 | $2.11M | $1.74M | - | -$364,000 | -17.27% | 0.0 |
| ACHN Achillion Pharmaceuticals Inc | 936,800 | $7.14M | $7.14M | - | - | - | 0.0 |
| AGIO Agios Pharmaceuticals Inc. | 100,000 | $3.38M | $3.23M | - | -$151,000 | -4.46% | +4.359% |
| ALT Altimmune, Inc. | 666,022 | $7.9M | $1.54M | - | -$6.36M | -80.52% | 0.0 |
| ANAB AnaptysBio Inc. | 2M | $22.52M | $93.17M | - | $70.65M | 313.75% | 0.0 |
| ANIP Ani Pharmaceuticals Inc. | 707,500 | $50.64M | $49.64M | - | -$1M | -1.98% | 0.0 |
| ARVN Arvinas Inc. | 538,658 | $3.78M | $3.67M | - | -$107,731.6 | -2.85% | 0.0 |
| AUPH Aurinia Pharmaceuticals Inc. | 12.23M | $99.92M | $204.6M | - | $104.68M | 104.77% | +0.722% |
| AVIR Atea Pharmaceuticals Inc. | 4.81M | $16.58M | $22.29M | - | $5.71M | 34.48% | 0.0 |
| AVNR AVNR | 1.56M | $3.2M | $3.2M | - | - | - | 0.0 |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for Kevin Tang?
The largest contributions to the portfolio's profits come from the following stocks: RXDX - $97.42M, Tarsus Pharmaceuticals Inc - $85.41M, LianBio - $49.65M, ImmunoGen Inc - $30.81M, and Merus N.V - $24.27M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Odonate Therapeutics Inc - $354.92M, La Jolla Pharmaceutical Co - $69.26M, Heron Therapeutics Inc - $55.22M, Biohaven Ltd - $47.34M, and Evolus Inc - $39.36M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does Kevin Tang's portfolio generate?
The portfolio generates substantial dividend income, with a total of $55.24M earned over time. The largest contributors to dividend income include LianBio - $44.96M, Flagstar Financial Corporation - $2.72M, GSK plc Sponsored ADR - $1.37M, SPDR S&P 500 ETF Trust - $691,024.8, and Sanofi American Depositary Receipt - $597,240. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are Kevin Tang's monthly returns?
Kevin Tang's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can Kevin Tang's strategy be considered aggressive or moderate?
Kevin Tang's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow Kevin Tang's strategy?
Kevin Tang's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
2026 © Marketlog. All Rights Reserved.
